Poll: Majority of Seniors and Taxpayers Support Lowering Costs and Increasing Access to Medicines Under Medicare Part D

Monday December 4, 2017

Fast and simple fix to the Part D discount program, placing biosimilars and branded biologics on a level playing field, would save taxpayers and increase use of lower-cost biosimilars

WASHINGTON, DC (Nov. 28, 2017) – The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), released a national poll today showing support for congressional action to lower out-of-pocket costs for patients and reduce federal spending for the Medicare Part D prescription drug benefit that covers most of America’s seniors.

According to the survey, there is an overwhelming belief by seniors and taxpayers that the government has a responsibility to lower health care costs for patients (nearly 9 in 10 seniors) and bring down costs overall for taxpayers (nearly 8 in 10).

However, the Medicare Part D program currently includes a provision that does the opposite: it encourages the use of costly brand-name medicines while discouraging the use of lower-cost medicines.

The medicines in question, known as “biosimilars,” are FDA-approved, safe, effective and affordable versions of more costly brand biologics. Much like generics, biosimilars offer a lower-priced alternative to brand-name biologic drugs. Experts estimate that increased entry and use of biosimilars could save as much as $250 billion over a 10-year period.

Under Medicare Part D, when patients’ drug spending reaches $4,100 in a year, they enter a coverage gap (or “donut hole”) where they pay a significantly higher share of drug costs until their spending reaches approximately $8,000 and they move on to the catastrophic coverage level.

This is where this provision of law comes into play: those makers of costlier brand biologics provide a 50 percent discount on the cost of branded medicines while patients are in the donut hole. In addition, current law allows that discount to be treated as if it were the patient’s own out-of-pocket spending – hastening passage through the donut hole into the catastrophic coverage phase where Medicare – that is, taxpayers – pays most of the cost.

This prevents makers of lower-priced biosimilars from offering comparable discounts and, even if they could, the law would not allow the discount to be treated as patient out-of-pocket spending. “This puts patients who are on a biosimilar at a disadvantage. Their medicine cannot by law be discounted, Medicare pays more and they remain in the gap longer,” said Christine Simmon, Executive Director of The Biosimilars Council. “The result: higher out-of-pocket costs for lower-cost medicines, higher premiums as the current incentive is to prescribe more costly medicines and higher taxes as Medicare pays more to cover the costs of branded medicines.”

A majority of seniors and taxpayers support a fix to Medicare Part D to allow biosimilar manufacturers to provide the same 50 percent discounts paid by their brand competitors. This simple fix would create a level playing field between biologics and less-expensive, FDA-approved biosimilars. And according to a recent study, this would result in lower out-of-pocket costs for patients and reduce federal spending by $1 billion over 10 years.

“Congress should amend the Part D coverage gap discount program to require biosimilar manufacturers to pay the 50 percent discounts paid by their brand competitors, allowing them to participate on a level playing field to compete for placement on Part D plan formularies,” added Simmon. “This is just common sense and good public policy. It will reduce both patient out-of-pocket costs and Part D program spending – saving taxpayers money.”

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.